X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (3) 3
cardiovascular disease (2) 2
coronary blood flow (2) 2
coronary circulation - drug effects (2) 2
dogs (2) 2
fibrin fibrinogen degradation products - pharmacology (2) 2
11 medical and health sciences (1) 1
abridged index medicus (1) 1
activating-factor acetylhydrolase (1) 1
activator (1) 1
aged (1) 1
alpha-tocopherol (1) 1
amino acid sequence (1) 1
angina (1) 1
angiotensin converting enzyme (1) 1
antioxidant (1) 1
arteriosclerosis (1) 1
ascites (1) 1
assaigs clínics de medicaments (1) 1
atherosclerotic plaque (1) 1
benzaldehydes (1) 1
benzaldehydes - administration & dosage (1) 1
benzaldehydes - adverse effects (1) 1
beta-carotene (1) 1
beta-tocopherol (1) 1
blood pressure - drug effects (1) 1
bukvattusot (1) 1
cardiac & cardiovascular systems (1) 1
cardiovascular agents (1) 1
cardiovascular diseases (1) 1
care and treatment (1) 1
cattle (1) 1
cbf, coronary vascular resistance (1) 1
cerebral infarction (1) 1
chronic diseases (1) 1
clinical medicine (1) 1
clinical trials (1) 1
clinical-outcomes (1) 1
coronary artery disease (1) 1
coronary artery disease - complications (1) 1
coronary artery disease - drug therapy (1) 1
coronary disease (1) 1
coronary disease - drug therapy (1) 1
coronary disease - mortality (1) 1
coronary diseases (1) 1
coronary heart disease (1) 1
coronary-heart-disease (1) 1
cvr, prostacyclin (1) 1
cyclic amp (1) 1
cyclic amp - blood (1) 1
death (1) 1
delta-tocopherol (1) 1
diagnostiska metoder (1) 1
dietary supplements (1) 1
dosage and administration (1) 1
double-blind method (1) 1
drug testing (1) 1
drug therapy (1) 1
enalaprilat - pharmacology (1) 1
endothelium-dependent vasodilation (1) 1
epithelial-cells (1) 1
epoprostenol - blood (1) 1
epoprostenol - metabolism (1) 1
female (1) 1
fibrin (1) 1
fibrin degradation product (1) 1
fibrin fibrinogen degradation products - chemistry (1) 1
fibrinogen (1) 1
fibrinogen - pharmacology (1) 1
fibrinopeptide b - pharmacology (1) 1
follow-up studies (1) 1
gamma-tocopherol (1) 1
general & internal medicine (1) 1
heart diseases (1) 1
hemodynamics - drug effects (1) 1
histamine release - drug effects (1) 1
humans (1) 1
in vitro techniques (1) 1
index medicus (1) 1
indomethacin - pharmacology (1) 1
infart de miocardi (1) 1
inhibitor (1) 1
ischemia (1) 1
kaplan-meier estimate (1) 1
klinisk medicin (1) 1
life sciences & biomedicine (1) 1
lipid-peroxidation (1) 1
lipoprotein (1) 1
lysine - chemistry (1) 1
lysine - metabolism (1) 1
malalties cardiovasculars (1) 1
malalties coronàries (1) 1
male (1) 1
mast cells - metabolism (1) 1
medical and health sciences (1) 1
medicin (1) 1
medicin och hälsovetenskap (1) 1
medicine, general & internal (1) 1
microvascular permeability (1) 1
middle aged (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by White, Harvey D and Held, Claes and Stewart, Ralph and Tarka, Elizabeth and Brown, Rebekkah and Davies, Richard Y and Budaj, Anzej and Harrington, Robert A and Steg, P. Gabriel and Ardissino, Diego and Armstrong, Paul W and Avezum, Alvaro and Aylward, Philip E and Bryce, Alfonso and Chen, Hong and Chen, Ming-Fong and Corbalan, Ramon and Dalby, Anthony J and Danchin, Nicolas and de Winter, Robbert J and Denchev, Stefan and Diaz, Rafael and Elisaf, Moses and Flather, Marcus D and Goudev, Assen R and Granger, Christopher B and Grinfeld, Liliana and Hochman, Judith S and Husted, Steen and Kim, Hyo-Soo and Koenig, Wolfgang and Linhart, Ales and Lonn, Eva and López-Sendón, José and Manolis, Athanasios J and Mohler, Emile R and Nicolau, José C and Pais, Prem and Parkhomenko, Alexander and Pedersen, Terje R and Pella, Daniel and Ramos-Corrales, Marco A and Ruda, Mikhail and Sereg, Mátyás and Siddique, Saulat and Sinnaeve, Peter and Smith, Peter and Sritara, Piyamitr and Swart, Henk P and Sy, Rody G and Teramoto, Tamio and Tse, Hung-Fat and Watson, David and Weaver, W. Douglas and Weiss, Robert and Viigimaa, Margus and Vinereanu, gos and Zhu, Junren and Cannon, Christopher P and Wallentin, Lars and Steg, Ph Gabriel and Bucan, Olga and Elfström, Charlotta and Hegg, Lisa and Jarosz, Marie and Krug-Gourley, Sue and Rudman, Jerry and Collins, Rory and Anderson, Jeffrey and DeMets, David and Ganz, Peter and Sandercock, Peter and Weber, Michael and Fisher, Marian and Buhr, Kevin and Diegel, Scott and Schultz, Melissa and Mahaffey, Kenneth W and Alexander, John H and Al-Khatib, Sana and Baron, Tomasz and Bergström, Olle and Bushnell, Cheryl and Christersson, Christina and Eggers, Kai and Fredlund, Bengt-Olov and Hagström, Emil and Hijazi, Ziad and Örndahl, Lovisa Holm and James, Stefan K and Jernberg, Tomas and Johnston, Nina and Lopez, Renato D and Mehta, Rajena H and Newby, Kristin L and Nordmark, Örjan and Oldgren, Jonas and Roe, Matthew T and Saldéen, Katarina and Stenborg, Anna and ... and The STABILITY Investigators and STABILITY Investigators and Medicinska fakulteten and Medicinska och farmaceutiska vetenskapsområdet and Kardiologi and Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm and Uppsala universitet and Institutionen för medicinska vetenskaper and Uppsala kliniska forskningscentrum (UCR)
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 18, pp. 1702 - 1711
Darapladib, an oral inhibitor of lipoprotein-associated phospholipase A2, was compared with placebo in 15,828 patients with stable coronary heart disease.... 
TRIAL | LIPOPROTEIN | MEDICINE, GENERAL & INTERNAL | THERAPY | ACTIVATING-FACTOR ACETYLHYDROLASE | OXIDIZED LDL | RISK | PHOSPHOLIPASE A | ATHEROSCLEROTIC PLAQUE | INHIBITOR | CLINICAL-OUTCOMES | Stroke - prevention & control | Double-Blind Method | Follow-Up Studies | Oximes - adverse effects | Phospholipase A2 Inhibitors - administration & dosage | Humans | Middle Aged | Kaplan-Meier Estimate | Oximes - administration & dosage | Male | Coronary Artery Disease - drug therapy | Coronary Disease - mortality | Phospholipase A2 Inhibitors - adverse effects | Benzaldehydes - adverse effects | Benzaldehydes - administration & dosage | Coronary Artery Disease - complications | Treatment Failure | Coronary Disease - drug therapy | Female | Aged | Myocardial Infarction - prevention & control | Prevention | Care and treatment | Ischemia | Dosage and administration | Research | Coronary heart disease | Cardiovascular agents | Myocardial infarction | Cerebral infarction | Phospholipase A2 | Clinical trials | Myocardial ischemia | Cardiovascular disease | Angina | Preventive medicine | Coronary artery disease | Phospholipase | Arteriosclerosis | Death | Plasma levels | Drug therapy | Heart diseases | Plaques | Malalties cardiovasculars | Infart de miocardi | Malalties coronàries | Assaigs clínics de medicaments | Cardiovascular diseases | Drug testing | Coronary diseases | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
Nutrition Research, ISSN 0271-5317, 10/2005, Volume 25, Issue 10, p. 877
Although the tocopherol content in food has been shown to be inversely associated with mortality from cardiovascular disease, dietary supplementation with... 
Vitamin E | Dietary supplements | Chronic diseases
Journal Article
Lakartidningen, ISSN 0023-7205, 02/1996, Volume 93, Issue 9, pp. 784 - 788
Journal Article
Lakartidningen, ISSN 0023-7205, 10/1998, Issue 44, pp. 4831 - 4833
Journal Article
Thrombosis Research, ISSN 0049-3848, 1983, Volume 30, Issue 3, pp. 213 - 218
A pentapeptide derived from fibrin(ogen), Ala-Arg-Pro-Ala-Lys, is known to increase microvascular permeability. This peptide induced dilation of bovine... 
peptides | cyclic AMP | fibrin(ogen) | prostacyclin | Cyclic AMP - blood | Fibrin Fibrinogen Degradation Products - pharmacology | Epoprostenol - metabolism | Animals | Cattle | Vasodilation - drug effects | In Vitro Techniques | Oligopeptides - pharmacology | Prostaglandins - metabolism
Journal Article
Thrombosis Research, ISSN 0049-3848, 1985, Volume 39, Issue 2, pp. 223 - 229
The hemodynamic effects of intracoronary administration of a fibrin (ogen)-derived peptide Bβ 30-43 (Arg-Pro-Ala-Pro-Pro-Pro-Ile-Ser-Gly-Gly-Gly-Tyr-Arg-Ala)... 
CBF, coronary vascular resistance | Coronary blood flow | PGI 2 | CVR, prostacyclin | PGI | Epoprostenol - blood | Animals | Regional Blood Flow - drug effects | Fibrinopeptide B - pharmacology | Dogs | Fibrinogen - pharmacology | Hemodynamics - drug effects | Coronary Circulation - drug effects | Indomethacin - pharmacology
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.